# A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

> **NCT03844074** · PHASE3 · COMPLETED · sponsor: **Outlook Therapeutics, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Wet Macular Degeneration

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** ranibizumab

## Key facts

- **NCT ID:** NCT03844074
- **Lead sponsor:** Outlook Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2020-07-23
- **Final completion:** 2020-08-13
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844074, "A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03844074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*